Rifaximin vs conventional oral therapy for hepatic encephalopathy: A meta-analysis

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 8

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

875

HTML

5559

Figures (1-4)

147

Tables (1-3)

149

Sum=6730

Feb 28, 2012 (publication date) through Apr 25, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Feb 28, 2012; 18(8): 767-777
Published online Feb 28, 2012. doi: 10.3748/wjg.v18.i8.767

Full Size Figure Download Figure

Figure 3 Adverse events experienced by patients treated with rifaximin vs control therapy. M-H: Mantel Haenszel.

Citation: Eltawil KM, Laryea M, Peltekian K, Molinari M. Rifaximin vs conventional oral therapy for hepatic encephalopathy: A meta-analysis. World J Gastroenterol 2012; 18(8): 767-777
URL: https://www.wjgnet.com/1007-9327/full/v18/i8/767.htm
DOI: https://dx.doi.org/10.3748/wjg.v18.i8.767